TMS Co Ltd
TMS Co Ltd has a highly liquid capital structure, with cash and equivalents amounting to ¥2.78 billion, representing 96.7% of total assets. The company has no long-term debt and a debt-to-equity ratio of 0.0, indicating a conservative leverage profile. The current ratio of 30.42 suggests strong short-term liquidity, with ample cash to cover liabilities. Profitability metrics are negative, with a return on equity of -25.84% and a return on assets of -24.99%. These figures indicate that the company is currently unprofitable and underperforming relative to its asset base. The operating and net losses of ¥700.7 million and ¥716.1 million, respectively, highlight the need for operational improvements or cost reductions to achieve profitability. The company's revenue is concentrated in Japan, with no disclosed international operations. This geographic concentration increases exposure to local economic and regulatory risks. No segment-specific revenue breakdown is available, but the company operates in a single business line focused on diagnostic reagents and services. Growth trajectory is not clearly defined in the available data, as no forward-looking revenue guidance is provided. The company has not disclosed specific growth initiatives or expansion plans. Analysts have assigned a mean price target of ¥620.00, with a strong buy recommendation, but this is based on limited data and does not reflect near-term earnings visibility. Risk factors include the company's current unprofitability and the absence of long-term debt, which may limit its ability to finance growth. There are no immediate liquidity or dilution flags, and the dilution risk is assessed as low. The company has not issued additional shares recently, and no dilution adjustments are applied in the valuation. Recent events include the publication of the latest financial results, which show continued operating and net losses. No significant regulatory or legal events were disclosed in the available data. The company has not issued new products or announced strategic partnerships in the most recent filings.
Business. TMS Co Ltd provides diagnostic reagents and services for infectious diseases, primarily in Japan, and generates revenue through the sale of diagnostic kits and related products.
Classification. TMS Co Ltd is classified under the Healthcare sector, specifically in the Biotechnology & Medical Research industry, with a classification confidence of 0.92.
- TMS Co Ltd has a highly liquid balance sheet with no long-term debt and a current ratio of 30.42.
- The company is currently unprofitable, with a return on equity of -25.84% and a return on assets of -24.99%.
- Revenue is concentrated in Japan, with no international operations disclosed.
- Analysts have assigned a strong buy rating, but the company has not provided forward-looking guidance.
- There are no immediate liquidity or dilution risks, and the company has not issued additional shares recently.
- --
- ## RATIONALES
- ```json
- No immediate filing-based liquidity or dilution flags were detected.